150 related articles for article (PubMed ID: 29469217)
1. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
[TBL] [Abstract][Full Text] [Related]
2. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
3. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
5. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
6. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
8. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
Abdelaziz AO; Shousha HI; Said EM; Soliman ZA; Shehata AA; Nabil MM; Abdelmaksoud AH; Elbaz TM; Abdelsalam FM
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1384-1388. PubMed ID: 30179227
[TBL] [Abstract][Full Text] [Related]
10. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
11. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
12. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
14. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
15. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
16. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
17. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
[TBL] [Abstract][Full Text] [Related]
18. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
19. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
[TBL] [Abstract][Full Text] [Related]
20. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
